A Phase II Study of AZD4877 (a Novel Anti-mitotic DRKS00004052
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer see http://clinicaltrials.gov/ct2/show/study/NCT00661609

Eligibility Bladder Cancer NCT00661609

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion criteria
C1512693 (UMLS CUI-1)
Urothelial cancer
Item
Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra).
boolean
UMLS CUI (CL363966)
C1519840 (UMLS CUI-1)
Stage IV
Item
Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy
boolean
C0441772 (UMLS CUI-1)
Prior chemotherapy
Item
Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting.
boolean
C1514457 (UMLS CUI-1)
Selfcare
Item
Ambulatory and capable of all selfcare more than 50% of waking hours
boolean
C0036592 (UMLS CUI-1)
Item Group
Exclusion criteria
C0680251 (UMLS CUI)
Prior treatment
Item
Prior treatment with investigational or standard anti-cancer agents, including radiotherapy, within 4 weeks prior to first dose of study medication; 6 weeks if prior systemic mitomycin, nitrosourea, or suramin.
boolean
C1514463 (UMLS CUI-1)
Bone marrow
Item
Inadequate bone marrow reserve
boolean
C0005953 (UMLS CUI-1)
Liver function
Item
Inadequate liver function in the presence of liver metastases
boolean
C0232744 (UMLS CUI)
Renal function
Item
Impaired renal function
boolean
C0341697 (UMLS CUI)